Imetelstat FDA approval

Imetelstat is approved by FDA for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia

May 2024: Imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, has been approved by the Food and Drug Administration for use in adults with low- to intermediate-1...
imetelstat-fda-approval

Scan the code

Tag: Imetelstat FDA approval

Home / Imetelstat FDA approval

Categories

Imetelstat is approved by FDA for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia

Information

Treatment

United States

India

Shanghai

Beijing

Hong Kong